Skip to main content

previous disabled Page of 3
and
  1. Article

    Open Access

    Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study

    Metabolic syndrome (MetS) is associated with cardiovascular disease in the general population and is also a potential cardiovascular risk factor in survivors of haematopoietic cell transplantation (HCT). We re...

    D. M. Greenfield, N. Salooja, C. Peczynski, S. van der Werf in Bone Marrow Transplantation (2021)

  2. No Access

    Article

    Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial

    We report the 12-year follow-up of the prospective randomized EBMT LYM1 trial to determine whether the benefit of brief duration rituximab maintenance (RM) on progression-free survival (PFS) in patients with r...

    R. Pettengell, R. Uddin, A. Boumendil, R. Johnson in Bone Marrow Transplantation (2021)

  3. No Access

    Article

    Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

    Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option in advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS). This study presents an updated analy...

    E. Domingo-Domenech, R. F. Duarte, A. Boumedil, F. Onida in Bone Marrow Transplantation (2021)

  4. No Access

    Article

    Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT

    Systemic anaplastic large cell lymphoma (sALCL) is a rare histological entity expressing the CD30 antigen that comprises around 11% of peripheral T-cell lymphoma. We analysed the outcome of patients with relap...

    E. Domingo-Domènech, A. Boumendil, F. Climent, H. Sengeloev in Bone Marrow Transplantation (2020)

  5. No Access

    Article

    Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

    Information regarding the curative role of allogeneic stem cell transplantation (allo-HCT) in systemic anaplastic large cell lymphoma (sALCL) is scarce. We analyzed the results of allo-HCT in patients with rel...

    E. Domingo-Domènech, A. Boumendil, F. Climent, G. Socié in Bone Marrow Transplantation (2020)

  6. No Access

    Article

    Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

    Autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care for patients with diffuse large B-cell lymphoma (DLBCL) who relapse/progress after first line chemoimmunotherapy. Long-ter...

    E. González-Barca, A. Boumendil, D. Blaise, M. Trněný in Bone Marrow Transplantation (2020)

  7. No Access

    Article

    EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL)

    Preliminary data suggest that allogeneic stem cell transplantation (allo-SCT) may be effective in T-prolymphocytic leukemia (T-PLL). The purpose of the present observational study was to assess the outcome of ...

    W. Wiktor-Jedrzejczak, J. Drozd-Sokolowska, D. J. Eikema in Bone Marrow Transplantation (2019)

  8. No Access

    Article

    Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD

    There is increasing evidence that endothelial dysfunction is involved in refractoriness of acute GvHD (aGvHD). Here we investigated the hypothesis that another endothelial complication, transplant-associated t...

    M Zeisbrich, N Becker, A Benner, A Radujkovic, K Schmitt in Bone Marrow Transplantation (2017)

  9. No Access

    Article

    Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party

    Relapse remains the most common cause of treatment failure in patients receiving autologous stem cell transplantation (ASCT) for follicular lymphoma (FL). The aim of this study was to evaluate the effect of ad...

    L Bento, A Boumendil, H Finel, S Le Gouill, S Amorim in Bone Marrow Transplantation (2017)

  10. Article

    Erratum: GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses

    Correction to: Bone Marrow Transplantation (2017) 52, 544–551; doi:10.1038/bmt.2016.305; published online 12 December 2016 Since the online publication of this article the authors realised there were errors in...

    L Sellner, M Brüggemann, M Schlitt, H Knecht, D Herrmann in Bone Marrow Transplantation (2017)

  11. No Access

    Article

    Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience

    J Meissner, H Finel, S Dietrich, A Boumendil, E Kanfer in Bone Marrow Transplantation (2017)

  12. No Access

    Article

    GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses

    Allogeneic stem cell transplantation (alloSCT) is used for treating patients with T-prolymphocytic leukemia (T-PLL). However, direct evidence of GvL activity in T-PLL is lacking. We correlated minimal residual...

    L Sellner, M Brüggemann, M Schlitt, H Knecht, D Herrmann in Bone Marrow Transplantation (2017)

  13. No Access

    Article

    Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation

    For young patients with high-risk CLL, BTK-/PI3K-inhibitors or allogeneic stem cell transplantation (alloHCT) are considered. Patients with a low risk of non-relapse mortality (NRM) but a high risk of failure ...

    J Schetelig, L C de Wreede, M van Gelder, N S Andersen in Bone Marrow Transplantation (2017)

  14. No Access

    Article

    Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation

    Even with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with curative potential for patients with CLL. Cure can be assessed by comparing long-...

    M van Gelder, L C de Wreede, M Bornhäuser, D Niederwieser in Bone Marrow Transplantation (2017)

  15. No Access

    Article

    Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT)

    Hematopoietic stem cell transplantation (HSCT) is used with increasing frequency in Europe with 40 000 transplants reported in 2014. Transplant-related mortality remains high in allogeneic HSCT (10–20%); high-...

    J R Passweg, H Baldomero, P Bader, C Bonini, S Cesaro in Bone Marrow Transplantation (2017)

  16. No Access

    Article

    Transplantation in CLL: what we can learn from a dinosaur

    P Dreger, E Montserrat in Bone Marrow Transplantation (2016)

  17. Article

    Open Access

    Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually

    A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey. T...

    J R Passweg, H Baldomero, P Bader, C Bonini, S Cesaro in Bone Marrow Transplantation (2016)

  18. No Access

    Article

    Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas

    Allogeneic hematopoietic cell transplantation (HCT) offers the chance of cure for patients with non-transformed follicular lymphoma (FL), but is associated with the risk of non-relapse mortality (NRM). The aim...

    F Heinzelmann, W Bethge, D W Beelen, M Engelhard, N Kröger in Bone Marrow Transplantation (2016)

  19. No Access

    Article

    Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party

    Little is known about the prognostic impact of prior paclitaxel therapy and response to induction chemotherapy defined as the regimen preceding high-dose chemotherapy (HDCT) for the salvage therapy of advanced...

    A Necchi, R Miceli, M Bregni, C Bokemeyer, L A Berger in Bone Marrow Transplantation (2016)

  20. No Access

    Article

    Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party

    In the era of chemoimmunotherapy, the optimal treatment paradigm for relapsed and refractory diffuse large B-cell lymphoma has been challenged. We reviewed the outcome of standard salvage therapy with an autol...

    S P Robinson, A Boumendil, H Finel, D Blaise, X Poiré in Bone Marrow Transplantation (2016)

previous disabled Page of 3